Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
10.11106/ijt.2021.14.2.98
- Author:
Young Kee SHONG
1
Author Information
1. Division of Endocrinology, Asan Medical Center, University of Ulsan, Seoul, Korea
- Publication Type:R E V IE W A R T IC L E
- From:International Journal of Thyroidology
2021;14(2):98-111
- CountryRepublic of Korea
- Language:English
-
Abstract:
Radioiodine refractory differentiated thyroid cancers are rare but they make a definite problem since they run relentlessly progressive course leading to death in a few years. Recent development of various tyrosine kinase inhibitors significantly prolonged the overall survival of these patients. Currently available agents are mostly directed to VEGFR and are not specific to thyroid cancer and their efficacy is somewhat limited for a certain period of time. Very recently developed specific agents can significantly prolong the overall survival of these patients without serious adverse event and probably this kind of precision medicine shall be available to all the patients in near future but at present successive salvage treatment using different angiogenesis inhibitors may be an alternative option.
